Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tulisokibart in Moderate to Severe Hidradenitis Suppurativa
NCT06956235Phase 2Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Jun 2025
- Primary completion
- Apr 2026
- Modality
- Monoclonal Antibodies
- Countries
- 15
01
Overview
A Phase 2 trial of tulisokibart in hidradenitis suppurativa (HS), sponsored by Merck & Co.. Started Jun 2025; status: active, not recruiting.
02
Drugs
tulisokibart
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on NCT06956235.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06956235.